Statins in Risk-reduction and Treatment of Cancer

Overview

Journal World J Clin Oncol

Publisher Baishideng Publishing Group

Specialty Oncology

Date 2020 Sep 4

PMID 32879845

Citations 47

Authors

Cristina I Barbalata

Lucia R Tefas

Marcela Achim

Ioan Tomuta

Alina S Porfire

Affiliations

Soon will be listed here.

Abstract

Statins, which are competitive inhibitors of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, reduce cholesterol blood levels and the risk of developing cardiovascular diseases and their related complications. In addition to this main activity, statins show pleiotropic effects such as antioxidant, anti-inflammatory and antiproliferative properties, with applications in many pathologies. Based on their antiproliferative properties, and studies have investigated their effects on various types of cancer (., breast cancer, prostate cancer, colorectal cancer, ovarian cancer, lung cancer) with different genetic and molecular characteristics. Many positive results were obtained, but they were highly dependent on the physiochemical properties of the statins, their dose and treatment period. Combined therapies of statins and cytotoxic drugs have also been tested, and synergistic or additive effects were observed. Moreover, observational studies performed on patients who used statins for different pathologies, revealed that statins reduced the risk of developing various cancers, and improved the outcomes for cancer patients. Currently, there are many ongoing clinical trials aimed at exploring the potential of statins to lower the mortality and the disease-recurrence risk. All these results are the foundation of new treatment directions in cancer therapy.

Citing Articles

Repurposing pitavastatin and atorvastatin to overcome chemoresistance of metastatic colorectal cancer under high glucose conditions.

Cheng W, Li P, Nguyen M, Lin Y, Huang Y, Cheng T Cancer Cell Int. 2025; 25(1):79.

PMID: 40050889 PMC: 11887183. DOI: 10.1186/s12935-025-03712-2.

The Effect of Atorvastatin on Oncogenic miRNAs in Hematological Malignancies: A Central Study.

Hashem J, Alsukhni F, Abushukair H, Ayesh M Biomolecules. 2025; 14(12.

PMID: 39766267 PMC: 11673652. DOI: 10.3390/biom14121559.

The Combined Inhibition of SREBP and mTORC1 Signaling Synergistically Inhibits B-Cell Lymphoma.

Zhu Z, Jiang W, Zhou J, Maldeney A, Liang J, Yang J Cancer Med. 2024; 13(21):e70342.

PMID: 39501600 PMC: 11538279. DOI: 10.1002/cam4.70342.

The Effect of Statins on Markers of Breast Cancer Proliferation and Apoptosis in Women with In Situ or Early-Stage Invasive Breast Cancer.

Kamal A, Boerner J, Assad H, Chen W, Simon M Int J Mol Sci. 2024; 25(17).

PMID: 39273534 PMC: 11395452. DOI: 10.3390/ijms25179587.

Impact of V9302, a Competitive Antagonist of Transmembrane Glutamine Flux on Reversal of Resistance in Breast Cancer Cell Lines.

Szemeredi N, Schelz Z, Horvath D, Racz B, Szatmari A, Muddather H Pharmaceutics. 2024; 16(7).

PMID: 39065573 PMC: 11280048. DOI: 10.3390/pharmaceutics16070877.

References

Ling Y, Yang L, Huang H, Hu X, Zhao C, Huang H . Prognostic Significance of Statin Use in Colorectal Cancer: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2015; 94(25):e908. PMC: 4504590. DOI: 10.1097/MD.0000000000000908. View

Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E . Endometrial cancer. Lancet. 2015; 387(10023):1094-1108. DOI: 10.1016/S0140-6736(15)00130-0. View

Theodosakis N, Langdon C, Micevic G, Krykbaeva I, Means R, Stern D . Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment-resistant melanoma, colorectal, and lung cancer. Pigment Cell Melanoma Res. 2018; 32(2):292-302. PMC: 6590911. DOI: 10.1111/pcmr.12742. View

Endres M . Statins and stroke. J Cereb Blood Flow Metab. 2005; 25(9):1093-110. DOI: 10.1038/sj.jcbfm.9600116. View

Chimento A, Casaburi I, Avena P, Trotta F, De Luca A, Rago V . Cholesterol and Its Metabolites in Tumor Growth: Therapeutic Potential of Statins in Cancer Treatment. Front Endocrinol (Lausanne). 2019; 9:807. PMC: 6348274. DOI: 10.3389/fendo.2018.00807. View

Saeedi Saravi S, Saeedi Saravi S, Arefidoust A, Dehpour A . The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration. Metab Brain Dis. 2017; 32(4):949-965. DOI: 10.1007/s11011-017-0021-5. View

Ding X, Zhang W, Li S, Yang H . The role of cholesterol metabolism in cancer. Am J Cancer Res. 2019; 9(2):219-227. PMC: 6405981. View

Kato S, Smalley S, Sadarangani A, Chen-Lin K, Oliva B, Branes J . Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase. J Cell Mol Med. 2009; 14(5):1180-93. PMC: 3822754. DOI: 10.1111/j.1582-4934.2009.00771.x. View

Zhang Y, Liang M, Sun C, Qu G, Shi T, Min M . Statin Use and Risk of Pancreatic Cancer: An Updated Meta-analysis of 26 Studies. Pancreas. 2019; 48(2):142-150. DOI: 10.1097/MPA.0000000000001226. View

10.

Licarete E, Sesarman A, Banciu M . Exploitation of pleiotropic actions of statins by using tumour-targeted delivery systems. J Microencapsul. 2015; 32(7):619-31. DOI: 10.3109/02652048.2015.1073383. View

11.

Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y . Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer. 2001; 84(7):886-91. PMC: 2363838. DOI: 10.1054/bjoc.2000.1716. View

12.

Terzi H, Altun A, Sencan M . comparison of the cytotoxic effects of statins on U266 myeloma cell line. Indian J Med Res. 2020; 150(6):630-634. PMC: 7038803. DOI: 10.4103/ijmr.IJMR_672_18. View

13.

Palko-Labuz A, Sroda-Pomianek K, Wesolowska O, Kostrzewa-Suslow E, Uryga A, Michalak K . MDR reversal and pro-apoptotic effects of statins and statins combined with flavonoids in colon cancer cells. Biomed Pharmacother. 2018; 109:1511-1522. DOI: 10.1016/j.biopha.2018.10.169. View

14.

Kim W, Kim M, Choi H, Yoon S, Lee M, Park K . Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs. 2001; 19(1):81-3. DOI: 10.1023/a:1006481423298. View

15.

Padegimas A, Clasen S, Ky B . Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity. Trends Cardiovasc Med. 2019; 30(1):22-28. PMC: 7287268. DOI: 10.1016/j.tcm.2019.01.006. View

16.

Vanova K, Boukalova S, Gbelcova H, Muchova L, Neuzil J, Gurlich R . Heme oxygenase is not involved in the anti-proliferative effects of statins on pancreatic cancer cells. BMC Cancer. 2016; 16:309. PMC: 4866069. DOI: 10.1186/s12885-016-2343-9. View

17.

Tan P, Wei S, Yang L, Tang Z, Cao D, Liu L . The effect of statins on prostate cancer recurrence and mortality after definitive therapy: a systematic review and meta-analysis. Sci Rep. 2016; 6:29106. PMC: 4935858. DOI: 10.1038/srep29106. View

18.

Wang K, Gerke T, Chen X, Prosperi M . Association of statin use with risk of Gleason score-specific prostate cancer: A hospital-based cohort study. Cancer Med. 2019; 8(17):7399-7407. PMC: 6885894. DOI: 10.1002/cam4.2500. View

19.

E J, Graber J, Lu S, Lin Y, Lu-Yao G, Tan X . Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: a Systematic Literature Review and Meta-analysis. Curr Med Chem. 2017; 25(22):2595-2607. PMC: 5638687. DOI: 10.2174/0929867324666170412145232. View

20.

Ramkumar S, Raghunath A, Raghunath S . Statin Therapy: Review of Safety and Potential Side Effects. Acta Cardiol Sin. 2016; 32(6):631-639. PMC: 5126440. DOI: 10.6515/acs20160611a. View